Erin A Bohula1, David A Morrow2, Robert P Giugliano2, Michael A Blazing3, Ping He2, Jeong-Gun Park2, Sabina A Murphy2, Jennifer A White3, Y Antero Kesaniemi4, Terje R Pedersen5, Adrian J Brady6, Yale Mitchel7, Christopher P Cannon2, Eugene Braunwald2. 1. TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: ebohula@partners.org. 2. TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 3. Duke Clinical Research Institute, Durham, North Carolina. 4. Department of Internal Medicine, Oulu University Hospital, Oulu, Finland. 5. Department of Endocrinology, Morbid Obesity and Preventative Medicine, Ullevål University Hospital, Oslo, Norway. 6. Department of Cardiology, Glasgow Royal Infirmary, Glasgow, United Kingdom. 7. Merck & Co., Inc., Kenilworth, New Jersey.
Abstract
BACKGROUND:Ezetimibe improves cardiovascular (CV) outcomes in patients stabilized after acute coronary syndrome (ACS) when added to statin therapy. After ACS, patients vary considerably in their risk for recurrent CV events. OBJECTIVES: This study tested the hypothesis that atherothrombotic risk stratification may be useful to identify post-ACS patients who have the greatest potential for benefit from the addition of ezetimibe to statin therapy. METHODS: The TIMI (Thrombolysis In Myocardial Infarction) Risk Score for Secondary Prevention (TRS 2°P) is a simple 9-point risk stratification tool, previously developed in a large population with atherothrombosis to predict CV death, myocardial infarction (MI), and ischemic stroke (CV death/MI/ischemic cerebrovascular accident [iCVA]). The current study applied this tool prospectively to 17,717 post-ACS patients randomized either to ezetimibe and simvastatin or to placebo and simvastatin in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Treatment efficacy was assessed by baseline risk for CV death/MI/iCVA, the IMPROVE-IT composite endpoints (CE), and individual component endpoints at 7 years. RESULTS: All 9 clinical variables in the TRS 2°P were independent risk indicators for CV death/MI/iCVA (p < 0.001). The integer-based scheme showed a strong graded relationship with the rate of CV death/MI/iCVA, the trial CE, and the individual components (p trend <0.0001 for each). High-risk patients (n = 4,393; 25%), defined by ≥3 risk indicators, had a 6.3% (95% confidence interval: 2.9% to 9.7%) absolute risk reduction in CV death/MI/iCVA at 7 years with ezetimibe/simvastatin, thus translating to a number-needed-to-treat of 16. Intermediate-risk patients (2 risk indicators; n = 5,292; 30%) had a 2.2% (95% confidence interval: -0.3% to 4.6%) absolute risk reduction. Low-risk patients (0 to 1 risk indicators; n = 8,032; 45%) did not appear to derive benefit from the addition of ezetimibe (p interaction = 0.010). Similar findings were observed for the IMPROVE-IT primary CE. CONCLUSIONS:Atherothrombotic risk stratification using the TRS 2°P identifies high-risk patients who derive greatest benefit from the addition of ezetimibe to statin therapy for secondary prevention after ACS. (Improved Reduction of Outcomes: Vytorin Efficacy International Trial [IMPROVE-IT]; NCT00202878).
RCT Entities:
BACKGROUND:Ezetimibe improves cardiovascular (CV) outcomes in patients stabilized after acute coronary syndrome (ACS) when added to statin therapy. After ACS, patients vary considerably in their risk for recurrent CV events. OBJECTIVES: This study tested the hypothesis that atherothrombotic risk stratification may be useful to identify post-ACS patients who have the greatest potential for benefit from the addition of ezetimibe to statin therapy. METHODS: The TIMI (Thrombolysis In Myocardial Infarction) Risk Score for Secondary Prevention (TRS 2°P) is a simple 9-point risk stratification tool, previously developed in a large population with atherothrombosis to predict CV death, myocardial infarction (MI), and ischemic stroke (CV death/MI/ischemic cerebrovascular accident [iCVA]). The current study applied this tool prospectively to 17,717 post-ACS patients randomized either to ezetimibe and simvastatin or to placebo and simvastatin in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Treatment efficacy was assessed by baseline risk for CV death/MI/iCVA, the IMPROVE-IT composite endpoints (CE), and individual component endpoints at 7 years. RESULTS: All 9 clinical variables in the TRS 2°P were independent risk indicators for CV death/MI/iCVA (p < 0.001). The integer-based scheme showed a strong graded relationship with the rate of CV death/MI/iCVA, the trial CE, and the individual components (p trend <0.0001 for each). High-risk patients (n = 4,393; 25%), defined by ≥3 risk indicators, had a 6.3% (95% confidence interval: 2.9% to 9.7%) absolute risk reduction in CV death/MI/iCVA at 7 years with ezetimibe/simvastatin, thus translating to a number-needed-to-treat of 16. Intermediate-risk patients (2 risk indicators; n = 5,292; 30%) had a 2.2% (95% confidence interval: -0.3% to 4.6%) absolute risk reduction. Low-risk patients (0 to 1 risk indicators; n = 8,032; 45%) did not appear to derive benefit from the addition of ezetimibe (p interaction = 0.010). Similar findings were observed for the IMPROVE-IT primary CE. CONCLUSIONS: Atherothrombotic risk stratification using the TRS 2°P identifies high-risk patients who derive greatest benefit from the addition of ezetimibe to statin therapy for secondary prevention after ACS. (Improved Reduction of Outcomes: Vytorin Efficacy International Trial [IMPROVE-IT]; NCT00202878).
Authors: Tracey G Simon; Kathleen E Corey; Christopher P Cannon; Michael Blazing; Jeong-Gun Park; Michelle L O'Donoghue; Raymond T Chung; Robert P Giugliano Journal: Int J Cardiol Date: 2018-05-26 Impact factor: 4.164
Authors: Nathan W Kong; Aakash Bavishi; Ansel Philip Amaral; Anjan Tibrewala; Arif Jivan; Philip Silberman; Neil J Stone Journal: Am J Cardiol Date: 2020-07-24 Impact factor: 2.778
Authors: Dylan L Steen; Irfan Khan; Katherine Andrade; Alexandra Koumas; Robert P Giugliano Journal: J Am Heart Assoc Date: 2022-04-27 Impact factor: 6.106
Authors: Eri Toda Kato; Christopher P Cannon; Michael A Blazing; Erin Bohula; Sema Guneri; Jennifer A White; Sabina A Murphy; Jeong-Gun Park; Eugene Braunwald; Robert P Giugliano Journal: J Am Heart Assoc Date: 2017-11-18 Impact factor: 5.501
Authors: Brian A Bergmark; Deepak L Bhatt; Eugene Braunwald; David A Morrow; Ph Gabriel Steg; Yared Gurmu; Avivit Cahn; Ofri Mosenzon; Itamar Raz; Erin Bohula; Benjamin M Scirica Journal: Diabetes Care Date: 2017-12-01 Impact factor: 19.112